Recently, a well-known global market research institute released the "2025-2030 Global Pharmaceutical Intermediates Industry Development Report". The report shows that with the intensification of global population aging, the rise in the incidence of chronic diseases and the continuous increase in investment in innovative drug research and development, the global pharmaceutical intermediates market scale has shown a steady expansion trend, with broad prospects for industry development. In 2025, the global pharmaceutical intermediates market scale successfully exceeded 80 billion US dollars, setting a new historical high.

The report predicts that from 2026 to 2030, the global pharmaceutical intermediates market will maintain a compound annual growth rate of more than 6.5%, and the market scale will exceed 110 billion US dollars by 2030. Among them, generic drug intermediates and innovative drug intermediates will become the two core driving forces for market growth. The large-scale production of generic drugs drives the demand for general intermediates to rise, while the acceleration of innovative drug research and development promotes the rapid development of the high-value-added intermediate market.

As the core production area of the global pharmaceutical intermediates industry, China occupies a dominant position in the global market by virtue of its improved industrial chain supporting facilities, mature production technology and cost advantages. Data show that in 2025, the scale of China's pharmaceutical intermediates market accounted for more than 30% of the global total scale, ranking first in the world, far exceeding traditional pharmaceutical intermediate production regions such as India and North America, and becoming the world's main supplier of pharmaceutical intermediates.

In recent years, Chinese pharmaceutical intermediate enterprises have continuously increased investment in technological research and development, achieved major breakthroughs in high-end fields such as high-activity intermediates and chiral intermediates, and the product quality and technical level have gradually aligned with international standards, with continuous improvement in export competitiveness. With the accelerated restructuring of the global supply chain, Chinese pharmaceutical intermediate enterprises have further seized the global market share and increased their export volume year by year by virtue of the advantage of a complete industrial chain.

Industry experts pointed out that in the next few years, with the transformation and upgrading of China's pharmaceutical industry and the continuous release of global pharmaceutical market demand, China's pharmaceutical intermediates industry will continue to maintain a growth trend, which is expected to further increase its global market share and promote China's transformation from a major producer of pharmaceutical intermediates to a powerful producer.